Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/cddis.2017.417 http://scihub22266oqcxt.onion/10.1038/cddis.2017.417 C5596596!5596596!28837141     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Death+Dis 2017 ; 8 (8): e3007- Nephropedia Template TP {{tp|p=28837141|t=2017. Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-?1/STAT3 axis-regulated EMT |pdf=|usr=}}{{28837141}} gab.com Text Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF- 1/STAT3 axis-regulated EMT JO: Cell Death Dis http://www.kidney.de/pget.php?&tw=1&pmid=28837141 #FOAvip Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4?6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR antagonist resistance have been focused on AR signaling. Therefore, the non-AR pathways on enzalutamide resistance remain largely unknown. By using C4-2, CWR22Rv1 and LNCaP cell lines, as well as mice bearing CWR22Rv1 xenografts treated with either enzalutamide or metformin alone or in combination, we demonstrated that metformin is capable of reversing enzalutamide resistance and restores sensitivity of CWR22Rv1 xenografts to enzalutamide. We showed that metformin alleviated resistance to enzalutamide by inhibiting EMT. Furthermore, based on the effect of metformin on the activation of STAT3 and expression of TGF-?1, we propose that metformin exerts its effects by targeting the TGF-?1/STAT3 axis. These findings suggest that combination of metformin with enzalutamide could be a more efficacious therapeutic strategy for the treatment of castration-resistant prostate cancer. Twit Text FOAVip Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF- 1/STAT3 axis-regulated EMT ????Cell Death Dis http://www.kidney.de/pget.php?&tw=1&pmid=28837141 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28837141 #FOAvip English Wikipedia <ref>{{Cite pmid|28837141}}</ref> Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-?1/STAT3 axis-regulated EMT #MMPMID28837141 Liu Q; Tong D; Liu G; Xu J; Do K; Geary K; Zhang D; Zhang J; Zhang Y; Li Y; Bi G; Lan W; Jiang J Cell Death Dis 2017[Aug]; 8 (8): e3007- PMID28837141show ga Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4?6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR antagonist resistance have been focused on AR signaling. Therefore, the non-AR pathways on enzalutamide resistance remain largely unknown. By using C4-2, CWR22Rv1 and LNCaP cell lines, as well as mice bearing CWR22Rv1 xenografts treated with either enzalutamide or metformin alone or in combination, we demonstrated that metformin is capable of reversing enzalutamide resistance and restores sensitivity of CWR22Rv1 xenografts to enzalutamide. We showed that metformin alleviated resistance to enzalutamide by inhibiting EMT. Furthermore, based on the effect of metformin on the activation of STAT3 and expression of TGF-?1, we propose that metformin exerts its effects by targeting the TGF-?1/STAT3 axis. These findings suggest that combination of metformin with enzalutamide could be a more efficacious therapeutic strategy for the treatment of castration-resistant prostate cancer. äMetformin reverses prostate cancer resistance to enzalutamide by targe(epmc).pdf DeepDyve Pubget Overpricing